Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:collaboratedWith |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:developedBy |
encapsulated cell therapies
|
| gptkbp:focusesOn |
gptkb:hemophilia_A
gptkb:mucopolysaccharidosis_type_I_(MPS_I) rare diseases cell-based therapies chronic diseases |
| gptkbp:foundedYear |
2015
|
| gptkbp:headquartersLocation |
gptkb:Cambridge,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sigilon Therapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:SIG-001
gptkb:SIG-005 |
| gptkbp:platform |
gptkb:Afibromer
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:SGTX
|
| gptkbp:website |
https://www.sigilon.com/
|
| gptkbp:bfsParent |
gptkb:Robert_Langer
|
| gptkbp:bfsLayer |
3
|